Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2000 Jul 10;150(1):165–176. doi: 10.1083/jcb.150.1.165

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2000 The Rockefeller University Press

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Glutamate inhibits EGFP-NF-M transport in transfected neurons. Points shown are distances traveled by EGFP-NF-M at 140–260 min after transfection. Cells were untreated or treated with 500, 50, or 30 μM glutamate. Glutamate was applied at the 140-min time point. The data sets shown are from one representative experiment and error bars are SEM. One-way ANOVA tests revealed no significant differences between untreated and glutamate-treated neurons at the 160-min time point (untreated versus 30 μM glutamate, P = 0.285; untreated versus 50 μM glutamate, P = 0.701; untreated versus 500 μM glutamate, P = 0.447). Significant differences between untreated and both 500 μM glutamate (P < 0.001) and 50 μM glutamate (P < 0.001), but not 30 μM glutamate (P = 0.132), treatments were detected at the 180-min time point. At later time points, significant differences were detected between untreated and all glutamate treatments (P < 0.001).

HHS Vulnerability Disclosure